Send to

Choose Destination
Pharmacol Ther. 1989;40(2):213-85.

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Author information

Department of Antiviral Chemotherapy, Research & Development Laboratories, Astra Alab AB, Södertälje, Sweden.


This article describes the antiviral properties of foscarnet (trisodium phosphonoformate) at the enzyme level as well as in cell cultures and in vivo. The mechanism of action against herpesvirus DNA polymerases and reverse transcriptases is outlined. Clinical studies using topical foscarnet against mucocutaneous herpes simplex virus infections are presented. The clinical use of intravenous foscarnet against severe viral infections caused by cytomegalovirus, hepatitis B virus and human immunodeficiency virus is discussed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center